Search Results - "Verges, B"

Adverse effects and safety of SGLT-2 inhibitors by Halimi, S, Vergès, B

“…Abstract In type 2 diabetes (T2DM), glycaemic control delays the development and slows the progression of complications. Although there are numerous…”
Get full text

Lipid disorders in type 1 diabetes by VERGES, B

“…Abstract Patients with type 1 diabetes (T1D) also present with lipid disorders. Quantitative abnormalities of lipoproteins are observed in T1D patients with…”
Get full text

Effects of anti-somatostatin agents on glucose metabolism by Vergès, B

“…Abstract The anti-somatostatin agents used to treat acromegaly, Cushing's disease and neuroendocrine tumours also have hyperglycaemic effects. This is…”
Get full text

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes by Sberna, A. L., Bouillet, B., Rouland, A., Brindisi, M. C., Nguyen, A., Mouillot, T., Duvillard, L., Denimal, D., Loffroy, R., Vergès, B., Hillon, P., Petit, J. M.

“…Aims To evaluate the application of the recently proposed recommendations by the European Association for the Study of the Liver, European Association for the…”
Get full text

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) by Capehorn, M.S., Catarig, A.-M., Furberg, J.K., Janez, A., Price, H.C., Tadayon, S., Vergès, B., Marre, M.

Get full text

GLP-1 receptor agonists in NAFLD by Petit, J.-M, Vergès, B

“…Abstract Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of…”
Get full text

High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS). The REHABDIAB study by Vergès, B., Patois-Vergès, B., Goueslard, K., Cottenet, J., Nguyen, A., Tatulashvili, S., Blonde, M.-C., Quantin, C.

Get full text

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? by Vergès, B, Charbonnel, B

“…Abstract Recent cardiovascular outcome trials – the LEADER with liragutide and SUSTAIN-6 with semaglutide – have shown significant reductions of major…”
Get full text

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings by Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., Vergès, B.

“…Despite the availability of a large number of therapeutic options throughout the world, rates of optimal glycaemic control in adult patients with type 2…”
Get full text

Potential risks associated with increased plasma plant-sterol levels by Vergès, B, Fumeron, F

“…Abstract The consumption of plant sterols is associated with a decrease in LDL cholesterol. However, it is also associated with an increase in plasma…”
Get full text

A low-carbohydrate high-fat diet initiated promptly after diagnosis provides clinical remission in three patients with type 1 diabetes by Bouillet, B., Rouland, A., Petit, J.M., Vergès, B.

Get full text

Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system by Vergès, B, Bonnard, C, Renard, E

“…Abstract Aim Glucagon-like peptide-1 (GLP-1) belongs to the incretin hormone family: in the presence of elevated blood glucose, it stimulates insulin secretion…”
Get full text

Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction by Benalia, M., Zeller, M., Mouhat, B., Guenancia, C., Yameogo, V., Greco, C., Yao, H., Maza, M., Vergès, B., Cottin, Y.

“…In patients with type 2 diabetes (T2D), glycaemic variability (GV), another component of glycaemic abnormalities, is a novel potentially aggravating factor for…”
Get full text

Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome by Vergès, B, Avignon, A, Bonnet, F, Catargi, B, Cattan, S, Cosson, E, Ducrocq, G, Elbaz, M, Fredenrich, A, Gourdy, P, Henry, P, Lairez, O, Leguerrier, A.M, Monpère, C, Moulin, P, Vergès-Patois, B, Roussel, R, Steg, G, Valensi, P

“…Abstract The Diabetes and Cardiovascular Disease study group of the Société francophone du diabète (SFD, French Society of Diabetes) in collaboration with the…”
Get full text

French Endocrine Society Guidance on endocrine side effects of immunotherapy by Castinetti, F, Albarel, F, Archambeaud, F, Bertherat, J, Bouillet, B, Buffier, P, Briet, C, Cariou, B, Caron, Ph, Chabre, O, Chanson, Ph, Cortet, C, Do Cao, C, Drui, D, Haissaguerre, M, Hescot, S, Illouz, F, Kuhn, E, Lahlou, N, Merlen, E, Raverot, V, Smati, S, Verges, B, Borson-Chazot, F

“…The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a…”
Get full text

Outcome in AN adult patients: A 13-year follow-up in 484 patients by Rigaud, D, Pennacchio, H, Bizeul, C, Reveillard, V, Vergès, B

“…Abstract Background To study the long-term prognosis of anorexia nervosa (AN), 484 adult AN patients were followed on a mean duration of 13 years. Results The…”
Get full text

Clinical interest of PPARs ligands: Particular benefit in type 2 diabetes and metabolic syndrome by VERGES, B

Get full text

Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study by Vergès, Bruno, Boureille, Françoise, Goudet, Pierre, Murat, Arnaud, Beckers, Albert, Sassolas, Geneviève, Cougard, Patrick, Chambe, Béatrice, Montvernay, Corinne, Calender, Alain

“…To date, data on pituitary adenomas in MEN type 1 (MEN1) still have to be evaluated. We analyzed the data of a large series of 324 MEN1 patients from a French…”
Get full text

Whole-exome sequencing identifies the first French MODY 6 family with a new mutation in the NEUROD1 gene by Bouillet, B., Crevisy, E., Baillot-Rudoni, S., Gallegarine, D., Jouan, T., Duffourd, Y., Petit, J.M., Vergès, B., Callier, P.

“…•Novel heterozygous missense mutation in Exon 2 of NEUROD1 gene.•First description of a MODY6 from a French family.•Whole exome sequencing screening for…”
Get full text

Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis by Petit, J.-M., Pedro, L., Guiu, B., Duvillard, L., Bouillet, B., Jooste, V., Habchi, M., Crevisy, E., Fourmont, C., Buffier, P., Hillon, P., Cercueil, J.-P., Verges, B.

“…Aim Non‐alcoholic fatty liver disease (NAFLD) is commonly associated with Type 2 diabetes. Recently, it has been suggested that NAFLD is also frequently…”
Get full text